Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URT035
MIFTS: 38

Urethral Benign Neoplasm

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Urethral Benign Neoplasm

About this section

MalaCards integrated aliases for Urethral Benign Neoplasm:

Name: Urethral Benign Neoplasm 12 15
Urethral Neoplasms 44 70
Malignant Neoplasm of Urethra 70
Neoplasm of Urethra 12
Urethral Carcinoma 70
Neoplasm. Urethra 12
Urethral Neoplasm 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:730
MeSH 44 D014523
NCIt 50 C3428
SNOMED-CT 67 126883004
UMLS 70 C0041971 C0153620 C0700101
Sources

Summaries for Urethral Benign Neoplasm

About this section
MalaCards based summary : Urethral Benign Neoplasm, also known as urethral neoplasms, is related to urethra leiomyoma and urethra cancer. An important gene associated with Urethral Benign Neoplasm is KRT20 (Keratin 20), and among its related pathways/superpathways are Cytoskeletal Signaling and ID signaling pathway. The drugs Gemcitabine and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and prostate, and related phenotype is renal/urinary system.

Sources

Related Diseases for Urethral Benign Neoplasm

About this section

Diseases related to Urethral Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
# Related Disease Score Top Affiliating Genes
1 urethra leiomyoma 32.3 MME CALD1
2 urethra cancer 30.6 KLK3 AMACR
3 mucinous bronchioloalveolar adenocarcinoma 10.4 KRT7 KRT20
4 leukoplakia of penis 10.4 KRT7 CEACAM5
5 anal paget's disease 10.4 KRT7 CEACAM5
6 epithelial predominant wilms' tumor 10.4 KRT7 AMACR
7 urinary bladder small cell neuroendocrine carcinoma 10.4 KRT7 KRT20
8 vulval paget's disease 10.4 KRT7 CEACAM5
9 eyelid carcinoma 10.4 KRT7 KRT20
10 jejunal neoplasm 10.4 KRT7 KRT20
11 bladder lymphoma 10.4 MME KRT20
12 jejunal cancer 10.4 KRT7 KRT20
13 bile duct cystadenocarcinoma 10.4 KRT7 CEACAM5
14 seminal vesicle cystadenoma 10.4 KLK3 CEACAM5
15 prostate signet ring cell adenocarcinoma 10.4 KLK3 CEACAM5
16 appendix adenocarcinoma 10.4 KRT7 KRT20
17 adenoid basal cell carcinoma 10.4 KRT7 CEACAM5
18 supine hypotensive syndrome 10.4 KRT7 KRT20
19 jejunal adenocarcinoma 10.4 KRT7 KRT20
20 appendiceal neoplasm 10.4 KRT7 CEACAM5
21 meibomian cyst 10.4 KRT7 KRT20
22 breast leiomyosarcoma 10.4 KRT7 CALD1
23 biliary papillomatosis 10.4 KRT7 CEACAM5
24 laryngeal mucoepidermoid carcinoma 10.4 KLK3 CEACAM5
25 urethra adenocarcinoma 10.4 KLK3 AMACR
26 vaginal endometrial stromal tumor 10.4 MME CALD1
27 mixed endometrial stromal and smooth muscle tumor 10.4 MME CALD1
28 fallopian tube leiomyoma 10.4 MME CALD1
29 fallopian tube benign neoplasm 10.4 MME CALD1
30 hidrocystoma 10.3 KRT7 CEACAM5
31 liver sarcoma 10.3 KRT7 CEACAM5
32 mixed epithelial stromal tumour 10.3 MME KRT7
33 prostate embryonal rhabdomyosarcoma 10.3 KLK3 CALD1
34 lung combined type small cell carcinoma 10.3 MME CALD1
35 bartholin's gland carcinoma 10.3 PAX8 KRT7
36 cervix endometriosis 10.3 PAX2 MME
37 vaginal adenoma 10.3 KRT7 KRT20
38 atrophoderma vermiculata 10.3 MME CEACAM5
39 urinary bladder villous adenoma 10.3 KRT7 KRT20 CEACAM5
40 vulva adenocarcinoma 10.3 KRT7 KRT20 CEACAM5
41 vaginal tubulovillous adenoma 10.3 KRT7 KRT20 CEACAM5
42 mucinous ovarian cystadenoma 10.3 KRT7 KRT20 CEACAM5
43 rectosigmoid junction neoplasm 10.3 KRT7 KRT20 CEACAM5
44 transverse colon cancer 10.3 KRT7 KRT20 CEACAM5
45 sigmoid neoplasm 10.3 KRT7 KRT20 CEACAM5
46 colonic lymphangioma 10.3 KRT7 KRT20 CEACAM5
47 prostate lymphoma 10.3 MME KLK3
48 neuroendocrine carcinoma 10.3 KRT7 KRT20 CEACAM5
49 anal canal adenocarcinoma 10.3 KRT7 KRT20 CEACAM5
50 vaginal glandular tumor 10.3 PGR CEACAM5

Comorbidity relations with Urethral Benign Neoplasm via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Cancer
Hydronephrosis Prostate Cancer
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Urethral Benign Neoplasm:



Diseases related to Urethral Benign Neoplasm
Sources

Symptoms & Phenotypes for Urethral Benign Neoplasm

About this section

MGI Mouse Phenotypes related to Urethral Benign Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.17 ESR1 FUT4 KRT7 PAX2 PAX8 THBD
Sources

Drugs & Therapeutics for Urethral Benign Neoplasm

About this section

Drugs for Urethral Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
3
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
4
Vinblastine Approved Phase 3 865-21-4 13342 241903
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
7
Bevacizumab Approved, Investigational Phase 3 216974-75-3
8 Dermatologic Agents Phase 2, Phase 3
9 Folic Acid Antagonists Phase 2, Phase 3
10 Antirheumatic Agents Phase 2, Phase 3
11 Antimitotic Agents Phase 3
12 Tubulin Modulators Phase 3
13
Liposomal doxorubicin Phase 3 31703
14 Halichondrin B Phase 3
15 Albumin-Bound Paclitaxel Phase 3
16 Angiogenesis Inhibitors Phase 3
17 Immunoglobulin G Phase 3
18 Immunoglobulins Phase 3
19 Immunoglobulins, Intravenous Phase 3
20 Antibodies Phase 3
21 Antibodies, Monoclonal Phase 3
22 Mitogens Phase 3
23 Endothelial Growth Factors Phase 3
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
26
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
27
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
28
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
29
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
30
Lonafarnib Approved, Investigational Phase 2 193275-84-2 148195
31
Ifosfamide Approved Phase 2 3778-73-2 3690
32
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
33
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
34
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
35
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
36
Ipilimumab Approved Phase 2 477202-00-9
37
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
38
nivolumab Approved Phase 2 946414-94-4
39
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
40
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
41
Fluorouracil Approved Phase 2 51-21-8 3385
42
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
43
leucovorin Approved Phase 2 58-05-9 6006
44
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
45
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
46
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
47
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
48
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Rubitecan Investigational Phase 2 91421-42-0

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
2 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
3 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
4 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
5 A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy Recruiting NCT04579224 Phase 3 Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
6 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
7 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
8 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
9 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
10 A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy Completed NCT00749892 Phase 2 Erlotinib Hydrochloride
11 A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer Completed NCT00661609 Phase 2 AZD4877
12 A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function. Completed NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
13 A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
14 A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
15 A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
16 Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer Completed NCT01031875 Phase 2 pazopanib hydrochloride
17 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder Completed NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
18 Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II Completed NCT00014144 Phase 2 gefitinib
19 Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
20 Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00066612 Phase 2 irinotecan hydrochloride
21 A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium Completed NCT00021099 Phase 2 ixabepilone
22 Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997 Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
23 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
24 Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
25 A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
26 A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium Completed NCT00407485 Phase 2
27 Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
28 Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
29 Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients With Locally Advanced or Recurrent Urothelial Malignancy Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
30 Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy Completed NCT00006111 Phase 2 cisplatin;fluorouracil
31 A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract Completed NCT00003175 Phase 2 fluorouracil
32 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
33 Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
34 A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
35 A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
36 Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
37 A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
38 A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER Completed NCT00009867 Phase 2 arsenic trioxide
39 Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
40 A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL-7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03513952 Phase 2 Atezolizumab
41 Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
42 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
43 A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
44 A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer Recruiting NCT03288545 Phase 1, Phase 2 enfortumab vedotin (EV);pembrolizumab;cisplatin;carboplatin;gemcitabine
45 A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma Active, not recruiting NCT01688999 Phase 2 Cabozantinib
46 Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer Active, not recruiting NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
47 Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
48 A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy Active, not recruiting NCT03219333 Phase 2 Enfortumab vedotin
49 LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Terminated NCT02612194 Phase 2 Crizotinib
50 Phase II Trial of Neoadjuvant Dose Dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer Terminated NCT01611662 Phase 2 gemcitabine hydrochloride;cisplatin

Search NIH Clinical Center for Urethral Benign Neoplasm

Inferred drug relations via UMLS 70 / NDF-RT 51 :


pembrolizumab

Cochrane evidence based reviews: urethral neoplasms

Sources

Genetic Tests for Urethral Benign Neoplasm

About this section
Sources

Anatomical Context for Urethral Benign Neoplasm

About this section

MalaCards organs/tissues related to Urethral Benign Neoplasm:

40
Breast, Lung, Prostate, Kidney, Liver, Ovary, Thymus
Sources

Publications for Urethral Benign Neoplasm

About this section

Articles related to Urethral Benign Neoplasm:

(show all 15)
# Title Authors PMID Year
1
Ureteral polyps protruding from the urethra. 61
33568095 2021
2
[Endoscopic electroexcision of benign urethral tumors in children]. 61
19432235 2009
3
Urethral wash cytopathology for monitoring patients after cystoprostatectomy with urinary diversion. 61
14681943 2003
4
[Benign neoplasms of the urethra in women]. 61
7474724 1994
5
Female urethra: MR imaging. 61
1898991 1991
6
Primary transitional cell carcinoma of the female urethra with features of clear cell adenocarcinoma. 61
4071854 1985
7
[Female primary urethral tumors]. 61
6542304 1984
8
Primary urethral neoplasms: review of 30 cases. 61
6259375 1981
9
Conservative management of low grade neoplasms of the male urethra: a preliminary report. 61
6766506 1980
10
[Urethral neoplasms in women]. 61
232312 1979
11
[Surgical treatment of recurrent urethral neoplasms after cystectomy for bladder carcinoma]. 61
539676 1979
12
[Urethral neoplasms in childhood]. 61
1011546 1976
13
[Pathologico-anatomical notes on the problem of after care in kidney and urethral neoplasms]. 61
4366591 1973
14
[Some diseases of the female urethra and its neoplasms. Early diagnosis of malignant urethral neoplasms]. 61
5365647 1969
15
[Primary urethral neoplasms in the female]. 61
13998784 1962
Sources

Variations for Urethral Benign Neoplasm

About this section
Sources

Expression for Urethral Benign Neoplasm

About this section
Search GEO for disease gene expression data for Urethral Benign Neoplasm.
Sources

Pathways for Urethral Benign Neoplasm

About this section

Pathways related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytoskeletal Signaling 4
11.41 KRT7 KRT5 KRT20 CALD1
2
ID signaling pathway 1
10.16 PAX8 PAX2
Sources

GO Terms for Urethral Benign Neoplasm

About this section

Biological processes related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 9.75 KRT7 KRT5 KRT20
2 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.6 PAX8 PAX2
3 replicative senescence GO:0090399 9.59 TP53 MME
4 urogenital system development GO:0001655 9.58 PAX8 PAX2
5 mesonephros development GO:0001823 9.57 PAX8 PAX2
6 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.56 TP53 ESR1
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.55 TP53 ESR1
8 intracellular steroid hormone receptor signaling pathway GO:0030518 9.54 PGR ESR1
9 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.52 PAX8 PAX2
10 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.51 PAX8 PAX2
11 pronephros development GO:0048793 9.49 PAX8 PAX2
12 metanephric epithelium development GO:0072207 9.48 PAX8 PAX2
13 metanephric nephron tubule formation GO:0072289 9.46 PAX8 PAX2
14 metanephric distal convoluted tubule development GO:0072221 9.43 PAX8 PAX2
15 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.4 PAX8 PAX2
16 positive regulation of metanephric DCT cell differentiation GO:2000594 9.37 PAX8 PAX2
17 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.32 PAX8 PAX2
18 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.26 PAX8 PAX2
19 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.16 PAX8 PAX2
20 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 8.96 PAX8 PAX2
21 pronephric field specification GO:0039003 8.62 PAX8 PAX2

Molecular functions related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.02 TP53 PGR PAX8 PAX2 ESR1
Sources

Sources for Urethral Benign Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....